

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1. (Currently amended) An isolated anti-PCI anti-Protein C inhibitor (PCI) antibody, having at least any one of: (a) activity to inhibit an inhibitory effect of Protein C inhibitor (PCI) on activated Protein C (aPC) activity, or (b) activity to inhibit an inhibitory effect of Protein C inhibitor (PCI) on the production of activated Protein C (aPC) by thrombin /thrombomodulin (Thr/TM) complex, comprising the complementarity determining region (CDR) sequences of any of one of (i) to (iii):

(i) heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 49, 50, and 51, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 55, 56, and 57, respectively;

(ii) heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 52, 53, and 54, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 58, 59, and 60, respectively; or

(iii) heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 25, 31, and 36, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 41, 45, and 48, respectively;

wherein the antibody inhibits PCI's inhibition of one or both of (a) activated Protein C (aPC) activity and (b) the production of aPC by thrombin/thrombomodulin (Thr/TM) complex,

2. (Currently amended) An The isolated anti-PCI antibody of claim 1, wherein the antibody inhibits PCI's inhibition of both (a) aPC activity and (b) the production of aPC by Thr/TM complex, having both (a) activity to inhibit an inhibitory effect of Protein C inhibitor (PCI) on activated Protein C (aPC) activity, and (b) activity to inhibit an inhibitory effect of

**Protein C inhibitor (PCI) on the production of activated Protein C (aPC) by thrombin
/thrombomodulin (Thr/TM) complex.**

3. (Currently amended) The An isolated antibody that competes with a second antibody for the second antibody's binding site on an antigen, wherein the CDRs of the second antibody are any one of (i) to (iii) of claim 1 or 2, wherein the antibody competes for the antibody binding site with an antibody comprising

(i) heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 49, 50, and 51, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 55, 56, and 57, respectively;

(ii) heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 52, 53, and 54, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 58, 59, and 60, respectively; or

(iii) heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 25, 31, and 36, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 41, 45 and 48, respectively;

wherein the isolated antibody inhibits PCI's inhibition of one or both of (a) aPC activity and (b) the production of aPC by Thr/TM complex, a variable region of an antibody selected from the group consisting of PC19G8, PC23A7, PC23D8, PC30G1, PC31E2, PC31F1, and PC39C6.

4. (Canceled)

5. (Currently amended) The isolated antibody of claim 1 or 2, wherein the antibody is selected from the group consisting of human antibodies, humanized antibodies, chimeric antibodies, antibody fragments, single-chain antibodies, and diabodies.

6. (Currently amended) A composition comprising the antibody of claim 1 or 2 and a pharmaceutically acceptable carrier.

7. (Currently amended) The composition of claim 6, further comprising Protein C and/or aPCactivated Protein C.

8-12. (Canceled)

13. (Currently amended) A kit ~~used to prevent or treat a disease that has developed and/or advanced due to a decrease or deficiency of activated Protein C activity, wherein the kit comprises comprising~~ (a) the antibody of claim 1 or 2, and (b) one or both of Protein C, and aPCactivated Protein C, or both.

14. (Currently amended) A kit ~~comprising used to prevent or treat a disease that has developed and/or advanced due to a decrease or deficiency of activated Protein C activity, wherein the kit comprises~~

(a) at least one of Protein C, activated Protein C, and ~~the~~an antibody comprising the CDR sequences of any one of (i) to (iii):

(i) heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOS: 49, 50, and 51, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 55, 56, and 57, respectively;

(ii) heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOS: 52, 53, and 54, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 58, 59, and 60, respectively; or

(iii) heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOS: 25, 31, and 36, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOS: 41, 45, and 48, respectively;

wherein the antibody inhibits PCI's inhibition of one or both of (A) activated aPC activity and (B) the production of aPC by Thr/TM complex of claim 1 or 2;

and

(b) a recording medium comprising a description [[on]] of the combined use of (1) (i) a therapeutically effective amount of Protein C and/or activated Protein C-aPC and (2) (ii) the antibody of (a) claim 1 or 2, or a link to the description.

15. (New) An isolated anti-PCI antibody comprising:

heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 49, 50, and 51, respectively; and

light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 55, 56, and 57, respectively,

wherein the antibody inhibits PCI's inhibition of aPC activity.

16. (New) An isolated anti-PCI antibody comprising:

heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 52, 53, and 54, respectively; and

light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 58, 59, and 60, respectively,

wherein the antibody inhibits PCI's inhibition of both (a) aPC activity and (b) the production of aPC by Thr/TM complex.

17. (New) An isolated anti-PCI antibody comprising:

heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 25, 31, and 36, respectively; and

light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 41, 45, and 48, respectively.

18. (New) The isolated anti-PCI antibody of claim 15, wherein the antibody comprises:

heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 22, 26, and 32, respectively; and

light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 37, 42, and 46, respectively.

19. (New) The isolated anti-PCI antibody of claim 15, wherein the antibody comprises:

heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 22, 27, and 32, respectively; and

light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 37, 42, and 46, respectively.

20. (New) The isolated anti-PCI antibody of claim 15, wherein the antibody comprises:

heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 23, 28, and 33, respectively; and

light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 38, 42, and 46, respectively.

21. (New) The isolated anti-PCI antibody of claim 16, wherein the antibody comprises:

heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 24, 29, and 34, respectively; and

light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 39, 43, and 47, respectively.

22. (New) The isolated anti-PCI antibody of claim 16, wherein the antibody comprises:

heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 24, 30, and 35, respectively; and

light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 40, 4,4 and 47, respectively.

23. (New) An isolated antibody that competes with a second antibody for the second antibody's binding site on an antigen, wherein the CDRs of the second antibody are:

heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 49, 50, and 51, respectively; and

light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 55, 56, and 57, respectively,

wherein the isolated antibody inhibits PCI's inhibition of aPC activity.

24. (New) An isolated antibody that competes with a second antibody for the second antibody's binding site on an antigen, wherein the CDRs of the second antibody are:

heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 52, 53, and 54, respectively; and

light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 58, 59, and 60, respectively;

wherein the isolated antibody inhibits PCI's inhibition of both (a) aPC activity and (b) the production of aPC by Thr/TM complex.

25. (New) An isolated antibody that competes with a second antibody for the second antibody's binding site on an antigen, wherein the CDRs of the second antibody are:

heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 25, 31, and 36, respectively; and

light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 41, 45, and 48, respectively.

wherein the isolated antibody inhibits PCI's inhibition of both (a) aPC activity and (b) the production of aPC by Thr/TM complex.

26. (New) The antibody of claim 3, wherein the antibody is selected from the group consisting of human antibodies, humanized antibodies, chimeric antibodies, antibody fragments, single-chain antibodies, and diabodies.

27. (New) A composition comprising the antibody of claim 3 and a pharmaceutically acceptable carrier.

28. (New) The composition of claim 27, further comprising Protein C and/or aPC.

29. (New) A kit comprising (a) the antibody of claim 3, and (b) either or both of Protein C and aPC.

30. (New) A kit comprising:

(a) at least one of Protein C, activated Protein C, and a first antibody that (1) inhibits PCI's inhibition of one or both of (A) aPC activity or (B) the production of aPC by Thr/TM complex, and (2) competes with a second antibody for the second antibody's binding site on an antigen, wherein the CDRs of the second antibody are any one of (i) to (iii):

(i) heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 49, 50, and 51, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 55, 56, and 57, respectively;

(ii) heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 52, 53, and 54, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 58, 59, and 60, respectively; or

(iii) heavy chain CDRs 1, 2, and 3 having the sequences of SEQ ID NOs: 25, 31, and 36, respectively; and light chain CDRs 1, 2, and 3 having the sequences of SEQ ID NO:s: 41, 45 and 48, respectively;

and

(b) a recording medium comprising a description of the combined use of (1) Protein C and/or aPC and (2) the first antibody, or a link to the description.